863567-20-8

Upstream product

• 494799-19-8 methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate 
• 877273-36-4 methyl 2-{2-[(tert-butoxycarbonyl)amino]phenyl}-1-(2-tert-butoxy-2-oxoethyl)-3-cyclohexyl-1H-indole-6-carboxylate 
• 774213-79-5 methyl 2-bromo-1-(2-tert-butoxy-2-oxoethyl)-3-cyclohexyl-1H-indole-6-carboxylate 
• 863566-97-6 13-cyclohexyl-6-oxo-6,7-dihydro-5H-benzo[5,6][1,4]diazepino[7,1-a]indole-10-carboxylic acid methyl ester 

Downstream Products

• 877274-04-9 C₂₇H₃₀N₄O₄S 
• 877285-47-7 13-cyclohexyl-6,7-dihydro-6-oxo-N-[(1-((5-bromothiazol-2-yl)carbamoyl)cyclopentyl)]-5H-indolo[1,2-d][1,4]benzodiazepine-10-carboxamide 
• 877384-84-4 C₃₈H₃₈N₄O₅ 
• 1373446-27-5 C₃₉H₄₀N₄O₅ 
• 877284-89-4 13-cyclohexyl-6,7-dihydro-N-[(1-carboxamidocyclopent-1-yl)]-6-oxo-5H-indolo[1,2-d][1,4]benzodiazepine-10-carboxamide 
• 877381-22-1 Ethyl 5-[[[1-[[(13-cyclohexyl-6,7-dihydro-6-oxo-5H-indolo[1,2-d][1,4]benzodiazepine-10-yl)carbonyl]amino]cyclopentyl]carbonyl]amino]-1-methyl-1H-indole-2-carboxylate 

Relevant academic research and scientific papers

Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus

Herein, we present initial SAR studies on a series of bridged 2-arylindole-based NS5B inhibitors. The introduction of bridging elements between the indole N1 and the ortho-position of the 2-aryl moiety resulted in conformationally constrained heterocycles

INHIBITORS OF HCV REPLICATION

Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of

FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR

The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

Inhibitors of HCV replication

Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds.